Salona Global Medical Device (TSE:EVMT) has released an update.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Evome Medical Technologies has reported a significant 39% projected revenue increase for Q2 2024 over the previous quarter, with a robust gross margin of 36% for April and May. In a strategic move to reduce debt, the company is planning to divest certain subsidiaries including DaMar, with future financial reports to focus on core assets Biodex and Damar. CEO Mike Seckler will discuss Q1 financials, Q2 progress, and future strategies in an upcoming shareholder update call.
For further insights into TSE:EVMT stock, check out TipRanks’ Stock Analysis page.